RxDoctor Payments Data

Maria Alfakir, MD

Internal Medicine · Haledon, NJNPI 1790993897

Payments from drug & device makers

$280in general payments, 2019–2025

Across 19 payments — averaging $14.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$115
  • Genentech USA, Inc.$56
  • GSK$42
  • Merck$14
  • Ascensia Diabetes Care US Inc.$14
  • Circassia Inc.$14
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$25491%
  • Education$259%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim8$115
Genentech USA, Inc.3$56
GSK3$42
Merck1$14
Ascensia Diabetes Care US Inc.1$14
Circassia Inc.1$14
Amgen1$13
AstraZeneca1$12

How this compares

$280 in reported general payments places this provider in the 45th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$72,322
Medicare patients
159
Services billed
1,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab19$194,740
Pirfenidone39$182,314
MounjaroTirzepatide135$144,712
JanuviaSitagliptin Phosphate123$110,340
JardianceEmpagliflozin79$73,984
Breztri AerosphereBudesonide/Glycopyr/Formoterol101$72,542
ProliaDenosumab42$67,625
EliquisApixaban75$60,638
FasenraBenralizumab11$59,716
LinzessLinaclotide104$58,615
Spiriva RespimatTiotropium Bromide73$58,506
Breo ElliptaFluticasone/Vilanterol90$43,444
SymbicortBudesonide/Formoterol Fumarate95$33,444
VascepaIcosapent Ethyl64$32,258
Janumet XrSitagliptin Phos/Metformin Hcl43$31,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Fasenra, Symbicort, Farxiga, Bevespi Aerosphere$12$202,051263 claims
MerckJanuvia, Janumet Xr, Belsomra$14$153,574194 claims
Boehringer IngelheimJardiance, Spiriva Respimat$115$132,490152 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta$42$76,467150 claims
AmgenProlia$13$67,62542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Haledon

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →